Based on the findings by Lynn and colleagues that FRβ exhibits an elevated expression level in TAMs isolated from individuals with ovarian cancer, these researchers suggested that FRβ-redirected CAR-Ts could be of therapeutic benefit for the elimination of such TAMs (89). The gene discussed is FOLR2; the disease is ovarian cancer.